50% off all subscriptions! ... left. Order NowOrder Now

Breakout Stocks of Week 49

NASDAQ was down last week (week 48) by -3.52% ending at 15 491.66 points after falling -565.78 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Meredith Corporation NYSE:MDP. This stock has had a buy signal since Sep 14, 2021 when the price was $41.65 and is so far up 41.66% to $59.00. Some other companies are on our watchlist to, among these are PetMed Express NASDAQ:PETS B. Riley Principal 150 Merger Corp. NYSE:BRPM Khosla Ventures Acquisition Co. II NASDAQ:KVSB and Astrazeneca PLC NYSE:AZN which all got a breakout pattern emerging.

Date Company Price Change
Nov 26, 2021 Meredith Corporation $59.00 $59.00 ( 26th Nov 2021 ) 0%
Nov 26, 2021 Petmed Express $29.06 $29.06 ( 26th Nov 2021 ) 0%
Nov 26, 2021 B. Riley Principal 150 Merger Corp. $10.35 $10.35 ( 26th Nov 2021 ) 0%
Nov 26, 2021 Khosla Ventures Acquisition Co. Ii $11.64 $11.64 ( 26th Nov 2021 ) 0%
Nov 26, 2021 Astrazeneca Plc $56.58 $56.58 ( 26th Nov 2021 ) 0%

Meredith Corporation

NYSE:MDP Strong Buy Candidate Score: 5.22
Strong Buy Candidate Score: 5.22 Nov 26, 2021

Meredith CorporationThe Meredith Corporation stock price gained 0.20% on the last trading day (Friday, 26th Nov 2021), rising from $58.88 to $59.00. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 0.41% from a day low at $58.80 to a day high of $59.04. The price has risen in 7 of the last 10 days and is up by 1.41% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 236 thousand more shares were traded than the day before. In total, 756 thousand shares were bought and sold for approximately $44.62 million.

On Nov 12, 2021 "Canaccord Genuity" gave "$3.20 - $3.00" rating for MDP. The price target was set to $58.29+0.2%.

Meredith Corporation holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.

About Meredith Corporation:
Meredith Corporation operates as a diversified media company that focuses primarily on the home and family marketplace in the United States. It operates in two segments, Local Media and National Media. The Local Media segment consists of 16 owned television stations, such as 7 CBS affiliates, 5 FOX affiliates, 2 MyNetworkTV affiliates, 1 NBC affiliate, 1 ABC affiliate, and 1 independent station, as well as 1 operated television station. This segment also includes 13 Websites, 13 mobile-optimized Websites, and approximately 40 applications focused on news, sports, and weather-related information. The National Media segment publishes magazines for women. This segment publishes approximately 20 subscription magazines that include Better Homes and Gardens, Parents, Family Circle, Allrecipes, Rachael Ray Every Day, Martha Stewart Living, Shape, and FamilyFun, as well as approximately 140 special interest publications under approximately 90 titles. Its portfolio also includes approximately 50 Websites, 30 mobile-optimized Websites, and 15 applications. In addition, this segment offers digital and customer relationship marketing services, such as specialized marketing products and services to America's companies. Further, it is involved in the provision of a consumer database, as well as custom content; and brand licensing activities and other related operations. The company was founded in 1902 and is headquartered in Des Moines, Iowa.

PetMed Express

NASDAQ:PETS Buy Candidate Score: 4.19
Buy Candidate Score: 4.19 Nov 26, 2021

PetMed ExpressThe PetMed Express stock price gained 2.14% on the last trading day (Friday, 26th Nov 2021), rising from $28.45 to $29.06. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 5.73% from a day low at $27.56 to a day high of $29.14. The price has fallen in 6 of the last 10 days and is down by -1.99% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 130 thousand more shares were traded than the day before. In total, 345 thousand shares were bought and sold for approximately $10.02 million.

On Nov 18, 2021 "Morgan Stanley" gave "$25.00" rating for PETS. The price target was changed from $29.37 to 2.5%.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for PetMed Express stock to perform well in the short-term.

About PetMed Express:
PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies through its Website. It markets its products through Internet; telephone contact center; and direct mail/print through 1-800-PetMeds catalogs, brochures, and postcards under various brands, including Frontline Plus, K9 Advantix II, Advantage II, Heartgard Plus, Sentinel, Revolution, and Rimadyl. PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida.

B. Riley Principal 150 Merger Corp.

NYSE:BRPM Buy Candidate Score: 3.72
Buy Candidate Score: 3.72 Nov 26, 2021

The B. Riley Principal 150 Merger Corp. stock price fell by -0.29% on the last day (Friday, 26th Nov 2021) from $10.38 to $10.35. and has now fallen 5 days in a row. During the day the stock fluctuated 1.36% from a day low at $10.26 to a day high of $10.40. The price has fallen in 6 of the last 10 days and is down by -0.86% for this period. Volume has increased on the last day by 45 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 324 thousand shares were bought and sold for approximately $3.36 million.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for B. Riley Principal 150 Merger Corp. stock to perform well in the short-term.

Khosla Ventures Acquisition Co. II

NASDAQ:KVSB Buy Candidate Score: 3.08
Buy Candidate Score: 3.08 Nov 26, 2021

The Khosla Ventures Acquisition Co. II stock price gained 5.43% on the last trading day (Friday, 26th Nov 2021), rising from $11.04 to $11.64. During the day the stock fluctuated 9.07% from a day low at $10.70 to a day high of $11.67. The price has been going up and down for this period, and there has been a -4.35% loss for the last 2 weeks. Volume fell on the last day by -550 thousand shares and in total, 614 thousand shares were bought and sold for approximately $7.15 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Khosla Ventures Acquisition Co. II stock to perform well in the short-term.

Astrazeneca PLC

NYSE:AZN Buy Candidate Score: 2.25
Buy Candidate Score: 2.25 Nov 26, 2021

Astrazeneca PLCThe Astrazeneca PLC stock price gained 0.43% on the last trading day (Friday, 26th Nov 2021), rising from $56.34 to $56.58. During the day the stock fluctuated 1.80% from a day low at $56.07 to a day high of $57.08. The price has fallen in 6 of the last 10 days and is down by -10.08% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 3 million more shares were traded than the day before. In total, 6 million shares were bought and sold for approximately $328.84 million.

On Nov 22, 2021 "Bryan, Garnier & Co" gave "" rating for AZN. The price target was changed from $56.59 to 0.1%.

Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.

About Astrazeneca PLC:
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide. Its marketed products comprise Accolate, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp, Duaklir Genuair, Eklira Genuair/Tudorza/Bretaris, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Rhinocort, Symbicort pMDI, and Symbicort Turbuhaler for respiratory, inflammation, and autoimmunity diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL, Tenormin3, and Zestril4 for cardiovascular disease; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic disease. The company’s marketed products also include Arimidex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex, as well as Casodex, Cosudex for oncology disease; Fluenz/FluMist, Fluenz Tetra/FluMist Quadrivalent1, Merrem/Meronem2, Synagis3, and Zinforo4 for infection disease; Diprivan, EMLA, Movantik/Moventig, Naropin, Seroquel IR, Seroquel XR, Vimovo1, Xylocaine, and Zomig for neuroscience disease; and Losec/Prilosec and Nexium for gastrointestinal disease. It primarily serves primary care and specialty care physicians through distributors and local representative offices. The company’s pipeline includes 146 projects, of which 125 are in the clinical phase of development. It has collaboration agreements with Celgene Corporation; Immunocore Limited; Eli Lilly and Company; Heptares Ltd.; Foundation Medicine, Inc., French National Institute of Health and Medical Research (Inserm); and FibroGen and Astellas. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.